RESPOND研究:可回收式Lotus瓣膜在常规临床实践中的安全性与有效性
RESPOND是一项前瞻性、开放标签、单臂研究,在常规临床实践中评估可重新定位且完全回收的Lotus瓣膜行TAVI治疗主动脉瓣狭窄的结局。共入组1014例患者,996例接受Lotus瓣膜。30天全因死亡率为2.6%(P<0.001 vs 预设性能目标),确认了该瓣膜在常规实践中的安全性和有效性。
要点
- 30天全因死亡率为2.6%,显著低于预设性能目标。
- 30天永久起搏器植入率30.0%,起搏器初治患者为34.6%。
- 出院时92%患者无或仅微量瓣周漏,无重度瓣周漏。
核心结论
- RESPOND研究结果确认了在常规临床实践中使用Lotus瓣膜行TAVI的安全性和有效性。
研究设计与样本
- 前瞻性、开放标签、单臂研究,在欧洲、新西兰和拉丁美洲的中心入组1014例患者,其中996例接受Lotus瓣膜。
主要发现
- 30天全因死亡率(意向治疗人群,主要终点)为2.6%(P<0.001 vs 预设性能目标)。
- 接受Lotus瓣膜的患者30天总体卒中率和致残性卒中率分别为3.0%和2.2%。
- 30天永久起搏器植入率在所有患者中为30.0%,在起搏器初治患者中为34.6%。
- 平均主动脉瓣跨瓣压差从基线37.7 ± 15.2 mmHg降至出院时10.8 ± 4.6 mmHg(P<0.001)。
- 出院时92%患者无或仅微量瓣周漏,0.3%患者有中度瓣周漏,7.7%患者有轻度瓣周漏,无重度瓣周漏。
关键数值与推荐
- 重新定位尝试率为29.2%,成功率为99%。
- 主动脉瓣面积从基线0.7 ± 0.2 cm2增至出院时1.8 ± 0.4 cm2(P<0.001)。
- 30天临床随访完成率为97.3%。
临床怎么用
- Lotus瓣膜可在常规临床实践中安全用于TAVI,术后血流动力学改善显著且瓣周漏发生率低。
局限性
- 单臂设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: RESPOND is a prospective, open-label, single-arm study evaluating the outcomes following transcatheter aortic valve implantation (TAVI) with the repositionable and fully retrievable Lotus Valve used in routine clinical practice for the treatment of patients with aortic valve stenosis. METHODS AND RESULTS: RESPOND enrolled 1014 patients at sites across Europe, New Zealand, and Latin America; 996 patients received a Lotus Valve (mean age: 80.8 years; 50.8% female; Society of Thoracic Surgeons score: 6.0 ± 6.9). Repositioning was attempted in 29.2% of patients, with 99% success. The rate of all-cause mortality in the intent-to-treat population at 30 days (primary endpoint) was 2.6% (P < 0.001 vs. pre-specified performance goal). Thirty-day clinical follow-up was completed for 97.3% of patients. Among patients who received a Lotus Valve, the 30-day overall and disabling stroke rates were 3.0% and 2.2%, respectively. The 30-day permanent pacemaker implantation rate was 30.0% in all patients, and 34.6% in pacemaker-naïve patients. Echocardiographic data at baseline and pre-discharge were assessed by an independent core laboratory. Mean aortic valve gradient declined from 37.7 ± 15.2 mmHg at baseline to 10.8 ± 4.6 mmHg at hospital discharge (P < 0.001). Aortic valve area increased from 0.7 ± 0.2 cm2 at baseline to 1.8 ± 0.4 cm2 at discharge (P < 0.001). At hospital discharge, paravalvular leak (PVL) was absent or trace in 92% of patients; no patients had severe PVL, 0.3% of patients exhibited moderate PVL, and 7.7% of patients had mild PVL. Clinical follow-up in RESPOND will extend to 5 years. CONCLUSION: The results of RESPOND confirm the safety and efficacy of TAVI with the Lotus Valve in routine clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov #NCT 02031302.
引用
- Falk V, Wöhrle J, Hildick-Smith D, et al. Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study. Eur Heart J. 2017. PMID: 28651336. doi:10.1093/eurheartj/ehx297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。